, Tracking Stock Market Picks
Enter Symbol:
Rating: LLY
Buy $115
down 85.00 %

Eli Lilly And Company (NYSE: LLY) upgraded to Buy with price target $115 by Jefferies

Friday,  Sep 18, 2015  10:25 AM ET by Dave Ficere

Jefferies upgraded Eli Lilly And Company (NYSE: LLY) to Buy with price target $115. Previously Jefferies rated Underperform Eli Lilly And Company (NYSE:
LLY) on 10/11/2013, when the stock price was $48.70. Since then, Eli Lilly And Company's stock price has gained 85% as of 09/18/2015's recent price of $90.04.
If you would have followed the previous Jefferies's recommendation on LLY, you would have lost 85% of your investment in 707 days.

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy